NewsRx

Search our medical news database

Heart Disease Therapy

Milestone II Registry reaffirms positive safety outcomes stent system

Published in Drug Week, October 1st, 2004

Angiotech Pharmaceuticals, Inc.'s, (ANPI, ANP) corporate partner, Boston Scientific, announced 6-month clinical findings from the European component of its Milestone II Registry.

Boston Scientific said it has enrolled nearly 3700 patients worldwide in the registry, which has been designed to assess physician usage patterns and evaluate outcome data for the Taxus Express(2) paclitaxel-eluting coronary stent system in "real world" patients.

The Milestone II registry has enrolled 1907 patients in Europe alone, where 118 centers were closely monitored. Analysis of the data was presented by Boston Scientific at the European Society of Cardiology's (ESC)...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook